|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online August 26, 2004
doi: 10.1242/10.1242/jcs.01324
Research Article |
Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland
* Author for correspondence (e-mail: adrian_robert.walmsley{at}pharma.novartis.com)
Accepted 24 May 2004
The central nervous system myelin components oligodendrocyte-myelin glycoprotein, myelin-associated glycoprotein and the Nogo-66 domain of Nogo-A inhibit neurite outgrowth by binding the neuronal glycosyl-phosphatidylinositol-anchored Nogo-66 receptor (NgR) that transduces the inhibitory signal to the cell interior via a transmembrane co-receptor, p75NTR. Here, we demonstrate that human NgR expressed in human neuroblastoma cells is constitutively cleaved in a post-ER compartment to generate a lipid-raft associated C-terminal fragment that is present on the cell surface and a soluble N-terminal fragment that is released into the medium. Mass spectrometric analysis demonstrated that the N-terminal fragment terminated just after the C-terminus of the ligand-binding domain of NgR. In common with other shedding mechanisms, the release of this fragment was blocked by a hydroxamate-based inhibitor of zinc metalloproteinases, but not by inhibitors of other protease classes and up-regulated by treatment with the cellular cholesterol depleting agent methyl-ß-cyclodextrin. The N-terminal fragment bound Nogo-66 and blocked Nogo-66 binding to cell surface NgR but failed to associate with p75NTR, indicative of a role as a Nogo-66 antagonist. Furthermore, the N- and C-terminal fragments of NgR were detectable in human brain cortex and the N-terminal fragment was also present in human cerebrospinal fluid, demonstrating that NgR proteolysis occurs within the human nervous system. Our findings thus identify a potential cellular mechanism for the regulation of NgR function at the level of the receptor.
Key words: Ectodomain shedding, Nogo-66 receptor, Zinc metalloproteinase
Related articles in JCS:
This article has been cited by other articles:
|
|
 |
|
  A. Jurewicz, M. Matysiak, C. S. Raine, and K. Selmaj Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis Neurology, January 23, 2007; 68(4): 283 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Ahmed, G. Mazibrada, R. J. Seabright, R. G. Dent, M. Berry, and A. Logan TACE-induced cleavage of NgR and p75NTR in dorsal root ganglion cultures disinhibits outgrowth and promotes branching of neurites in the presence of inhibitory CNS myelin FASEB J, September 1, 2006; 20(11): 1939 - 1941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Ahmed, E. L. Suggate, E. R. Brown, R. G. Dent, S. J. Armstrong, L. B. Barrett, M. Berry, and A. Logan Schwann cell-derived factor-induced modulation of the NgR/p75NTR/EGFR axis disinhibits axon growth through CNS myelin in vivo and in vitro Brain, June 1, 2006; 129(6): 1517 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Logan, Z. Ahmed, A. Baird, A. M. Gonzalez, and M. Berry Neurotrophic factor synergy is required for neuronal survival and disinhibited axon regeneration after CNS injury Brain, February 1, 2006; 129(2): 490 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Venkatesh, O. Chivatakarn, H. Lee, P. S. Joshi, D. B. Kantor, B. A. Newman, R. Mage, C. Rader, and R. J. Giger The Nogo-66 Receptor Homolog NgR2 Is a Sialic Acid-Dependent Receptor Selective for Myelin-Associated Glycoprotein J. Neurosci., January 26, 2005; 25(4): 808 - 822. [Abstract] [Full Text] [PDF]
|
|
